The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer. [electronic resource]
Producer: 20081107Description: 417-23 p. digitalISSN:- 1537-453X
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bone Neoplasms -- drug therapy
- Capecitabine
- Carcinoma, Renal Cell -- drug therapy
- Deoxycytidine -- administration & dosage
- Disease-Free Survival
- Female
- Fluorouracil -- administration & dosage
- Humans
- Kidney Neoplasms -- drug therapy
- Liver Neoplasms -- drug therapy
- Lung Neoplasms -- drug therapy
- Lymphatic Metastasis
- Male
- Maximum Tolerated Dose
- Middle Aged
- Nephrectomy
- Survival Rate
- Thalidomide -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.